Core Insights - Plus Therapeutics, Inc. is advancing its clinical trials for REYOBIQ™ and preparing for the launch of the CNSide® CSF assay platform, with a focus on central nervous system cancers [1][2] Financial Overview - The cash balance increased to $9.9 million as of March 31, 2025, compared to $0.1 million at December 31, 2024 [6] - The company raised gross proceeds of $15 million through private placement financing and received a $2 million grant from CPRIT to support the development of REYOBIQ™ [7] - Grant revenue for Q1 2025 was $1.1 million, down from $1.7 million in Q1 2024 [13] - The total operating loss for Q1 2025 was $3.5 million, slightly higher than the $3.3 million loss in the same period of 2024 [13] - The net loss for Q1 2025 was $17.4 million, or $(1.19) per share, compared to a net loss of $3.3 million, or $(0.75) per share, in Q1 2024 [13][18] Clinical Development Highlights - REYOBIQ™ is being evaluated for recurrent glioblastoma and leptomeningeal metastases in ongoing clinical trials [9] - Updated interim data presented at a conference in May 2025 indicated safety and clinical benefits of REYOBIQ™ for patients with leptomeningeal metastases [7] - Phase 1 trial results published in Nature Communications showed that patients receiving a radiation dose greater than 100 Gy had a median overall survival of 17 months, more than double the standard of care [7] Management and Strategic Developments - The company strengthened its management team with key appointments, including Kyle Guse to the Board of Directors and Dr. Michael Rosol as Chief Development Officer [7] - Russell Bradley was appointed as President and General Manager of CNSide Diagnostics, focusing on the commercialization of the CSF assay platform [7] Product and Technology Overview - REYOBIQ™ is a novel injectable radiotherapy designed for targeted delivery of high-dose radiation to CNS tumors, potentially improving patient outcomes compared to existing therapies [9] - CNSide Diagnostics is developing the CNSide™ CSF assay platform to identify tumor cells in cerebrospinal fluid, with plans for commercialization in the U.S. in 2025 [10]

WEST DES MOINES, Iowa, May 30, 2025 (GLOBE NEWSWIRE) -- Athene Holding Ltd. (“Athene”) today announced it will redeem all outstanding shares of its 6.375% Fixed-Rate Reset Perpetual Non-Cumulative Preferred Stock, Series C (the “Series C Preferred Stock”), and the corresponding depositary shares (CUSIP: 04686J 309; ISIN: US04686J3095) (the “Depositary Shares”), each representing a 1/1,000th interest in a share of the Series C Preferred Stock. The Series C Preferred Stock will be redeemed on the upcoming div ...

ATHENS, Greece, May 30, 2025 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (“OET” or the “Company”) (NYSE:ECO / OSE:OET) today announced that the 2025 Annual Meeting of the Shareholders of the Company (the “Annual Meeting”) was duly held on May 30, 2025 and that all proposals on the agenda were approved. At the Annual Meeting, the shareholders of the Company: (i) Elected the following eight directors to serve until the next annual meeting of shareholders or until their successors are elected and qualified: ...

Group 1 - Mondelēz International has joined the 100+ Accelerator, becoming the sixth corporate partner alongside AB InBev, The Coca-Cola Company, Colgate-Palmolive, Danone, and Unilever [1][3] - The 100+ Accelerator, launched in 2018, aims to rapidly pilot and scale solutions in areas such as regenerative agriculture, circular packaging, and energy efficiency, having supported approximately 190 startups across more than 40 countries [2][9] - The addition of Mondelēz International enhances the program's cross-industry collaboration, indicating a trend among major brands to work together on sustainable innovation [3][7] Group 2 - The 100+ Accelerator provides startups with funding, mentorship, and opportunities to pilot innovations in real-world corporate environments, allowing entrepreneurs to refine and scale their technologies [4][9] - Recent innovations from the program include support for smallholder agricultural sustainability, low-emission logistics, circular systems for packaging, and water efficiency solutions [8][9] - Applications for the seventh cohort of the 100+ Accelerator are now open, inviting entrepreneurs globally to participate [5]

TORONTO and HAIFA, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that Professor Nahshon Knoller M.D., senior clinical advisor to the Company, will be presenting at the prestigious annual meeting of the American Spinal Injury Association (“ASIA”), where he will discuss the Company’s plans for future clinical trials in 2026 in the field of acute spinal cord injuries (“SCI”) for ExoPTEN, a first-in-clas ...

Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET tha ...

Silvano Fashion Group AS (hereinafter SFG) notified on 30.04.2025 in its stock exchange news available here https://view.news.eu.nasdaq.com/view?id=1359951&lang=en that SFG will disclose the audited consolidated annual report for the 2024 financial year as soon as practically possible, which is expected to happen on 31.05.2025 at the latest. Due to reasons not attributable to SFG the audited consolidated annual report for the 2024 financial year will be disclosed on 06.06.2025. Silvano Fashion Group ASTel + ...

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Vancouver, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1) announces that it is extending the closing of it non-brokered, listed issuer financing exemption private placement (the “Private Placement”) for minimum gross proceeds of C$750,000, and maximum gross proceeds of up to C$1,117,495 through the issuance of up to 11,174,950 units (each a “Unit”) ...

Selected Financial Indicators Summarized selected financial indicators of the Group for Q1of 2025 compared to Q1of 2024 and 31.03.2025 compared to 31.12.2024 were as follows: in thousands of EUR03m 202503m 2024Change Revenue 12 01613 904-13.6%Gross Profit5 8447 789-25.0%Operating profit1 4023 548-60.5%EBITDA2 1654 298-49.6%Net profit for the period2 9692 9161.8%Net profit attributable equity holders of the Parent company2 7522 5547.8%Earnings per share (EUR)0,080,07<td style="width:63.34px;;t ...

Core Insights - PRFoods has faced a challenging third quarter in the 2024/2025 financial year due to market volatility and a poor economic climate in Estonia, yet the company has managed to increase profitability and reduce expenses [1][3] - The bond restructuring plan has been approved, allowing production units to focus on business development [2][6] Financial Performance - The unaudited consolidated revenue for the third quarter was 3.7 million euros, a 3% decrease from the previous financial year [3] - EBITDA improved from -0.2 million euros in the 2023/2024 financial year to -0.1 million euros, while the net loss decreased from -0.7 million euros to -0.5 million euros [3] - For the first nine months of the 2024/2025 financial year, the unaudited consolidated revenue was 15.1 million euros, representing a 20% increase compared to the same period last year [4] - EBITDA from operating activities increased to 0.6 million euros, and the net loss for the nine months was -0.9 million euros, compared to -2.1 million euros in the previous financial year [4] Operational Insights - The UK production unit, John Ross Jr., continues to operate profitably, while the Estonian production unit has shown improvement despite a significant decrease in demand for fish products due to the economic downturn [5] - The company acknowledges that efficiency improvements are significant achievements in the current volatile market [5] Key Ratios - Key financial ratios for the third quarter include a gross margin of 18.1%, EBITDA margin of -3.5%, and a net margin of -14.5% [7] - The balance sheet shows a net debt of 13.3 million euros and an equity ratio of 10.4% as of March 31, 2025 [8] Consolidated Financial Position - Total assets amounted to 20.971 million euros, with total liabilities at 18.787 million euros as of March 31, 2025 [9] - The company reported a net loss of 0.535 million euros for the third quarter, with a loss per share of -0.01 euros [10]